Literature DB >> 20626301

Detection of serum free light chains: the problem with antigen excess.

Markus Bosmann1, Jürgen Kössler, Herbert Stolz, Ulrich Walter, Stefan Knop, Udo Steigerwald.   

Abstract

BACKGROUND: In recent years, measurement of serum immunoglobulin free light chains (FLCs) has greatly facilitated diagnosis and monitoring of various plasma cells dyscrasias, including multiple myeloma. Detection of FLCs by nephelometry depends on the formation of immune complexes. However, it is known that if the antigen (free light chain) is present in great excess, non-precipitating immune complexes can be formed and be detected poorly. This may lead to inaccurate test results.
METHODS: Serum samples from 91 patients were subjected prospectively to the detection of free κ and λ light chains by automated nephelometry. A standard dilution of 1:100 was paralleled by a 1:2000 dilution. In addition, samples with values below the effective range (1:100) were subjected to a 1:20 dilution in order to calculate the κ/λ ratio.
RESULTS: Here, we report the incidence of antigen excess in a cohort of 91 patients with a high proportion of monoclonal abnormalities. A standard dilution (1:100) of free light κ chains from a patient with monoclonal immunoglobulin A κ gammopathy were missed repeatedly. In a second patient (with myeloproliferative disease and an apparent incidental FLC monoclonal gammopathy of undetermined significance) free λ chains were also substantially underestimated in the standard dilution. Hence, the incidence of erroneously low test results due to antigen excess was 2.20%.
CONCLUSIONS: We found a significantly higher incidence of falsely low test results due to antigen excess than reported previously. Antigen excess may result in erroneous interpretations in sera subjected to nephelometric analysis. Therefore, clinical decisions should not be based solely on a single assay, especially if FLC testing includes only one dilution of the serum sample. Instead, several parallel dilutions should be recommended for screening of patients.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20626301     DOI: 10.1515/CCLM.2010.283

Source DB:  PubMed          Journal:  Clin Chem Lab Med        ISSN: 1434-6621            Impact factor:   3.694


  6 in total

1.  Serum free light chain quantitative assays: Dilemma of a biomarker.

Authors:  Giovanni Cigliana; Francesca Gulli; Cecilia Napodano; Krizia Pocino; Elena De Santis; Luigi Colacicco; Iole Cordone; Laura Conti; Umberto Basile
Journal:  J Clin Lab Anal       Date:  2017-04-26       Impact factor: 2.352

2.  Defining the impact of individual sample variability on routine immunoassay of serum free light chains (sFLC) in multiple myeloma.

Authors:  S H K Murng; L Follows; P Whitfield; J A Snowden; K Swallow; K Green; R Sargur; W Egner
Journal:  Clin Exp Immunol       Date:  2013-02       Impact factor: 4.330

3.  The analytical performance evaluation of Freelite™ Human Kappa Free and Human Lambda Free on the SPAPLUS™ immunoturbidimetric analyzer.

Authors:  Kyong-Ho Cha; Yang Bo Sim; Hyojin Chae; Hae-il Park; Myungshin Kim; Yonggoo Kim
Journal:  J Clin Lab Anal       Date:  2014-01-29       Impact factor: 2.352

4.  Polyclonal free light chains: a biomarker of inflammatory disease or treatment target?

Authors:  Judith A Brebner; Robert A Stockley
Journal:  F1000 Med Rep       Date:  2013-02-01

5.  Effect of specimen type on free immunoglobulin light chains analysis on the Roche Diagnostics cobas 8000 analyzer.

Authors:  Louis S Nelson; Bryan Steussy; Cory S Morris; Matthew D Krasowski
Journal:  Springerplus       Date:  2015-12-08

6.  Clinical comparisons of two free light chain assays to immunofixation electrophoresis for detecting monoclonal gammopathy.

Authors:  Han-Sung Kim; Hyun Soo Kim; Kyu-Sung Shin; Wonkeun Song; Hyo Jung Kim; Hyeong Su Kim; Min-Jeong Park
Journal:  Biomed Res Int       Date:  2014-05-27       Impact factor: 3.411

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.